Showing results (331-340 of 384) with videos related to
Sort By:
Pageof 39
ESMO Open|January 21, 2020
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysisAndrea Napolitano, Salvatore Provenzano, Chiara Colombo, et al.Cell Reports|January 28, 2014
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversityVanessa Almendro, Yu-Kang Cheng, Amanda Randles, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialGeorge D Demetri, Margaret von Mehren, Robin L Jones, et al.The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic SarcomasBreelyn A Wilky, Gary K Schwartz, Michael S Gordon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.Sarcoma|November 16, 2017
SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath TumorsChristine S Higham, Seth M Steinberg, Eva Dombi, et al.Oncoimmunology|December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.Journal for Immunotherapy of Cancer|September 1, 2021
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomesBrett A Schroeder, Natalie A LaFranzo, Bonnie J LaFleur, et al.Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.Pageof 39